Centessa Pharmaceuticals Plc (CNTA)
NASDAQ:CNTA
CNTA Stock Chart & Stats
$27.58
-$0.91(-5.25%)
At close: 4:00 PM EST
$27.58
-$0.91(-5.25%)
Day’s Range― - ―
52-Week Range$9.60 - $30.58
Previous CloseN/A
Volume658.98K
Average Volume (3M)1.26M
Market Cap
$3.71B
Enterprise Value$5.29B
Total Cash (Recent Filing)$246.21M
Total Debt (Recent Filing)$118.26M
Price to Earnings (P/E)―
Beta1.00
Next Earnings
May 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding146,075,740
10 Day Avg. Volume1,504,030
30 Day Avg. Volume1,255,574
Financial Highlights & Ratios
PEG Ratio-0.26
Price to Book (P/B)4.78
Price to Sales (P/S)0.00
P/FCF Ratio-13.49
Enterprise Value/Market Cap1.43
Enterprise Value/Revenue352.37
Enterprise Value/Gross Profit357.82
Enterprise Value/Ebitda-23.26
Forecast
1Y Price Target
$46.00Price Target Upside66.79% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
EPS Forecast (FY)-1.64
Revenue Forecast (FY)$2.25M
Bulls Say, Bears Say
Bulls Say
Clinical-stage Pipeline Progress (OX2R Agonists)Advancing ORX750 into a registrational program marks a structural de-risking milestone for Centessa’s neuroscience franchise. Moving from exploratory to registrational trials increases the likelihood of later regulatory value creation and directs R&D resources toward a coherent, higher-priority commercial pathway over the next 2–3 years.
High Reported Gross ProfitabilitySustained gross margins near 94% indicate collaboration and product-related revenues incur low direct costs, implying that if Centessa converts pipeline successes to recurring sales or higher-value licensing, incremental revenue could flow to the bottom line efficiently and support long-term margin sustainability once commercialized.
Improved Funding Flexibility Via ATM AmendmentAccess to a $250M ATM increases strategic optionality to smooth financing over time, reducing acute refinancing risk. For a clinical-stage biotech with ongoing trials, this structural flexibility helps maintain program funding, enabling multi-year R&D plans without forcing large, single-event capital raises.
Bears Say
Large And Persistent Cash BurnVery negative operating and free cash flow reflects ongoing funding of multiple clinical programs and is a durable constraint on the business. Continued burn necessitates periodic external financing, increasing execution risk if capital markets tighten and potentially delaying programs if funding is constrained.
Deep Unprofitability And Negative MarginsLarge operating losses show the company is far from self-sustaining while clinical-stage, meaning profitability depends on successful clinical outcomes and future commercialization. This structural deficit limits reinvestment capacity and increases reliance on external capital to fund R&D and regulatory milestones over the medium term.
Equity Erosion And Ongoing Dilution RiskDeclining equity alongside heavy losses signals cumulative dilution and capital consumption. Coupled with recent ADS offerings and ATM capacity, shareholders face structural dilution risk as the company repeatedly taps markets to fund operations until products generate sustainable cash flow.
Centessa Pharmaceuticals News
CNTA FAQ
What was Centessa Pharmaceuticals Plc’s price range in the past 12 months?
Centessa Pharmaceuticals Plc lowest stock price was $9.60 and its highest was $30.58 in the past 12 months.
What is Centessa Pharmaceuticals Plc’s market cap?
Centessa Pharmaceuticals Plc’s market cap is $3.71B.
When is Centessa Pharmaceuticals Plc’s upcoming earnings report date?
Centessa Pharmaceuticals Plc’s upcoming earnings report date is May 18, 2026 which is in 47 days.
How were Centessa Pharmaceuticals Plc’s earnings last quarter?
Currently, no data Available
Is Centessa Pharmaceuticals Plc overvalued?
According to Wall Street analysts Centessa Pharmaceuticals Plc’s price is currently Undervalued.
Does Centessa Pharmaceuticals Plc pay dividends?
Centessa Pharmaceuticals Plc does not currently pay dividends.
What is Centessa Pharmaceuticals Plc’s EPS estimate?
Centessa Pharmaceuticals Plc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Centessa Pharmaceuticals Plc have?
Centessa Pharmaceuticals Plc has 146,075,740 shares outstanding.
What happened to Centessa Pharmaceuticals Plc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Centessa Pharmaceuticals Plc?
Currently, no hedge funds are holding shares in CNTA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Centessa Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$46.00 (66.79% Upside)
$46.00 (66.79% Upside)
Blogger Sentiment
Bullish
CNTA Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 3.2M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.7%
Last 30 Days ▲ 9.4%
Last 30 Days ▲ 9.4%
News Sentiment
Very Bullish
Bullish news 82%
Bearish news 18%
Bearish news 18%
Technicals
SMA
Positive
20 days / 200 days
Momentum
97.79%
12-Months-Change
Fundamentals
Return on Equity
-67.68%
Trailing 12-Months
Asset Growth
-26.47%
Trailing 12-Months
Company Description
Centessa Pharmaceuticals Plc
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; and SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B. The company also has emerging pipeline products under clinical proof of concept stage comprising LB101, a PD-L1xCD47 LockBody, as well as LB201, a PD-L1xCD3 LockBody, which are designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; ZF874, a small molecule pharmacological chaperone folding corrector of the Z variant of alpha-1-antitrypsin in Phase I clinical development for the treatment of alpha-1-antitrypsin deficiency; MGX292, a recombinant modified BMP9 replacement protein designed to overcome the deficiency in BMP9 signaling in Pulmonary Arterial Hypertension; and OX2R Agonists that are oral and intranasal selective orexin receptor 2 agonists designed to leverage structural insights and to directly target the underlying pathophysiology of orexin neuron loss in Narcolepsy Type 1. In addition, the company has exploratory pipeline products under clinical proof of concept stage containing CBS001, an anti-LIGHT antibody, which preferentially binds the inflammatory membrane form of LIGHT in inflammatory/fibrotic diseases; and CBS004, a humanized mAb specific to BDCA2, expressed exclusively on plasmacytoid dendritic cells in systemic sclerosis, systemic lupus erythematosus, and other autoimmune diseases. Centessa Pharmaceuticals plc was incorporated in 2020 and is based in Altrincham, the United Kingdom.
CNTA Stock 12 Month Forecast
Average Price Target
$46.00
▲(66.79% Upside)
Technical Analysis
Ultragenyx Pharmaceutical
―
Xenon
―
Apellis Pharmaceuticals
―
Scholar Rock Holding
―
Immunovant
―
Ownership Overview
1.05% Insiders
12.00% Mutual Funds
73.72% Other Institutional Investors
11.90% Public Companies and
Individual Investors